Profile data is unavailable for this security.
About the company
Beijing Sun-Novo Pharmaceutical Research Co Ltd is a China-based company primarily engaged in the provision of preclinical and integrated clinical research and development services for pharmaceuticals. The Company's main businesses cover comprehensive research and development services in drug development, generic drug development and consistency assessment. The Company's services mainly comprise drug discovery, pharmacology and pharmacodynamics, pharmacy research, clinical research and bioanalysis. The Company's pharmaceutical research services cover the fields of drug discovery, small nucleic acid drug development, peptide drug research and development, and sustained-release formulation development. The Company's clinical trials and bioanalyses services include phase I-IV clinical trials, bioequivalence (BE) trials and others. The Company mainly conducts its businesses in the domestic market.
- Revenue in CNY (TTM)1.02bn
- Net income in CNY133.01m
- Incorporated2009
- Employees1.36k
- LocationBeijing Sun-Novo Pharmaceutical Research Co Ltd1F, Building 7, No. 79Shuangying West Road, Science ParkChangping DistrictBEIJING 102200ChinaCHN
- Phone+86 1 060748199
- Fax+86 1 060748199
- Websitehttp://www.sun-novo.com/
More ▼
Mergers & acquisitions
| Acquired company | 688621:SHH since announced | Transaction value |
|---|---|---|
| Jiangsu Langyan Life Science Holdings Co Ltd | 27.87% | 222.30m |
Data delayed at least 15 minutes, as of Mar 04 2026.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qingdao Vland Biotech INC | 1.39bn | 83.57m | 3.79bn | 1.57k | 45.48 | 2.13 | -- | 2.72 | 0.329 | 0.329 | 5.50 | 7.01 | 0.4585 | 3.89 | 3.65 | -- | 3.76 | 4.84 | 6.11 | 6.94 | 44.19 | 45.52 | 8.20 | 9.54 | 0.877 | -- | 0.2648 | 32.35 | 10.16 | 9.30 | -22.39 | -4.23 | -2.71 | -6.89 |
| Hinova Pharmaceuticals Inc | 23.61m | -144.57m | 3.98bn | 173.00 | -- | 3.61 | -- | 168.39 | -1.46 | -1.46 | 0.2384 | 11.12 | 0.0171 | 2.37 | 5.59 | 136,467.70 | -10.45 | -26.09 | -11.68 | -29.74 | 95.50 | -- | -612.36 | -78,863.60 | 6.90 | -- | 0.0883 | -- | -- | -38.67 | 32.18 | -- | 139.77 | -- |
| Bide Pharmatech Co Ltd | 1.27bn | 153.31m | 4.75bn | 738.00 | 29.76 | 2.37 | -- | 3.74 | 1.76 | 1.76 | 14.49 | 22.03 | 0.5167 | 0.8804 | 5.25 | 1,720,520.00 | 6.24 | 7.02 | 7.52 | 8.29 | 43.30 | 42.16 | 12.07 | 13.13 | 2.78 | -- | 0.1055 | 48.73 | 0.9298 | 34.69 | 7.17 | -- | 80.65 | -- |
| Hangzhou Alltest Biotech Co Ltd | 881.63m | 294.76m | 5.28bn | 969.00 | 17.87 | 1.35 | -- | 5.99 | 3.72 | 3.72 | 11.12 | 49.21 | 0.2098 | 2.38 | 6.39 | 909,839.10 | 7.02 | 19.18 | 7.57 | 21.66 | 55.00 | 57.79 | 33.47 | 38.82 | 8.34 | -- | 0.0093 | 35.14 | 14.83 | 29.13 | 67.50 | 30.99 | 71.01 | -- |
| Shouyao Holdings Co Ltd | 2.14m | -206.73m | 5.35bn | 178.00 | -- | 8.17 | -- | 2,496.67 | -1.39 | -1.39 | 0.0144 | 4.40 | 0.0025 | 0.0366 | 0.2625 | 12,033.88 | -23.67 | -32.53 | -27.20 | -36.25 | 95.74 | 99.43 | -9,651.03 | -3,370.01 | 6.42 | -- | 0.0044 | -- | -24.61 | -19.34 | -14.21 | -- | 49.71 | -- |
| Shanghai Aladdin Biochemical Tech Co Ltd | 599.98m | 83.95m | 5.54bn | 652.00 | 67.00 | 5.19 | -- | 9.23 | 0.2485 | 0.2485 | 1.78 | 3.21 | 0.2785 | 0.4218 | 4.55 | 920,216.30 | 5.04 | 7.81 | 6.90 | 8.60 | 62.21 | 60.61 | 18.09 | 24.95 | 1.53 | 9.15 | 0.3541 | 48.33 | 32.44 | 20.55 | 15.07 | 9.17 | 41.61 | -- |
| GemPharmatech Co Ltd | 752.70m | 121.51m | 6.15bn | 1.58k | 49.89 | 2.79 | -- | 8.17 | 0.3007 | 0.3007 | 1.86 | 5.37 | 0.2807 | 4.51 | 1.88 | 476,993.40 | 4.53 | 7.69 | 5.42 | 8.96 | 61.84 | 68.17 | 16.14 | 25.58 | 3.17 | -- | 0.1295 | 21.94 | 10.39 | 28.94 | -30.89 | 25.88 | 20.02 | -- |
| Jiangsu Yahong Meditech Co Ltd | 279.02m | -362.17m | 6.51bn | 391.00 | -- | 3.67 | -- | 23.32 | -0.642 | -0.642 | 0.4933 | 3.10 | 0.125 | 11.16 | 4.19 | 713,603.90 | -16.84 | -14.30 | -19.15 | -15.01 | 72.22 | 73.78 | -134.65 | -703.80 | 4.96 | -- | 0.1545 | -- | 1,365.55 | -- | 4.09 | -- | 50.48 | -- |
| Beijing Sun-Novo Pharma Research Co Ltd | 1.02bn | 133.01m | 6.56bn | 1.36k | 48.22 | 5.64 | -- | 6.45 | 1.21 | 1.21 | 9.23 | 10.38 | 0.4745 | 35.48 | 1.28 | 653,956.40 | 6.04 | 11.39 | 10.49 | 18.82 | 48.60 | 53.31 | 12.72 | 19.66 | 1.78 | 9.97 | 0.3355 | 11.29 | 15.70 | 35.80 | -3.98 | 30.21 | 3.50 | -- |
| Shanghai Medicilon Inc | 1.08bn | -231.86m | 8.69bn | 2.27k | -- | 4.21 | -- | 8.05 | -1.75 | -1.75 | 8.04 | 15.36 | 0.3759 | 8.56 | 1.68 | 459,338.00 | -8.08 | 3.66 | -9.99 | 4.63 | 16.27 | 31.15 | -21.49 | 6.67 | 2.19 | -- | 0.1508 | 40.97 | -24.01 | 18.22 | -896.21 | -- | 2.54 | -- |
| Bio-Thera Solutions Ltd | 845.32m | -368.84m | 8.82bn | 1.17k | -- | 18.23 | -- | 10.44 | -0.8908 | -0.8908 | 2.04 | 1.17 | 0.3702 | 0.7722 | 5.96 | -- | -16.15 | -16.38 | -33.76 | -22.22 | 74.99 | 77.05 | -43.63 | -62.11 | 0.4617 | -34.12 | 0.573 | -- | 5.44 | 302.90 | -29.34 | -- | 11.14 | -- |
Data as of Mar 04 2026. Currency figures normalised to Beijing Sun-Novo Pharmaceutical Research Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
11.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2025 | 3.26m | 4.02% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 1.92m | 2.37% |
| Essence Fund Co., Ltd.as of 30 Jun 2025 | 1.44m | 1.78% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2025 | 989.69k | 1.22% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 924.65k | 1.14% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 224.81k | 0.28% |
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2025 | 202.34k | 0.25% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 176.69k | 0.22% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 176.29k | 0.22% |
| First-Trust Fund Management Co., Ltd.as of 30 Jun 2025 | 158.07k | 0.20% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
